• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

KRCA-0008

CAS No. 1472795-20-2

KRCA-0008 ( KRCA 0008 | KRCA0008 )

产品货号. M12023 CAS No. 1472795-20-2

KRCA-0008 是一种有效的选择性 ALK 抑制剂,IC50 为 12 nM(wt ALK)。

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
2MG ¥245 有现货
5MG ¥392 有现货
10MG ¥550 有现货
25MG ¥1079 有现货
50MG ¥1851 有现货
100MG ¥2961 有现货
500MG 获取报价 有现货
1G 获取报价 有现货
1 mL x 10 mM in DMSO ¥525 有现货

生物学信息

  • 产品名称
    KRCA-0008
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    KRCA-0008 是一种有效的选择性 ALK 抑制剂,IC50 为 12 nM(wt ALK)。
  • 产品描述
    KRCA-0008 is a potent, selective ALK inhibitor with IC50 of 12 nM (wt ALK), also is potent against various ALK mutants, including L1196M, F1174L, R1275Q, and C1156Y (IC50=5-75 nM); weakly inhibits IR (IC50=210 nM), inhibits H3122 and BaF3 EML4-ALK L1196M cell proliferation with IC50 of 80 and 68 nM, respectively; demonstrates in vivo efficacy comparable to Crizotinib in xenograft mice model, has drug-like properties without hERG concerns.
  • 体外实验
    Cell Proliferation Assay Cell Line:H3122 and H1993 cell lines Concentration:200 nM Incubation Time:6 hours Result:Inhibited cell proliferation of H3122 and H1993 cells with IC50s of 0.08 and 3.6 nM, respectively.Cell Proliferation Assay Cell Line:NPM-ALK-positive ALCL cell lines (Karpas-299 and SU-DHL-1) and U937 NPM ALK-negative lymphoma cell line Concentration:200 nM Incubation Time:72 hoursResult:Inhibited proliferation of Karpas-299, SU-DHL-1 and U937 cells with GI50s of 12 nM, 3 nM and 3.5 μM, respectively.Western Blot Analysis Cell Line:Karpas-299 and SU-DHL-1 cell lines Concentration:0, 10, 100 and 1000 nMIncubation Time:4 hoursResult:Completely suppressed phosphorylation of ALK and its effectors at a dose of 100 nM in NPM-ALK-positive ALCL cells.Apoptosis AnalysisCell Line:SU-DHL-1 cell line Concentration:0-1 μM Incubation Time:72 hours Result:Dose-dependently increased cspase-3/7 activities and induced cell apoptosis.Cell Cycle Analysis Cell Line:Karpas-299 and SU-DHL-1 cell lines Concentration:0-100 nM Incubation Time:48 hours Result:Induced G0/G1 cell cycle arrest in ALCL cells expressing NPM-ALK.
  • 体内实验
    Animal Model:NOD/SCID mice with Karpas-299 xenograftsDosage:25 and 50 mg/kg Administration:Oral gavage; 25 and 50 mg/kg twice a day; for two weeks Result:Significantly inhibited tumor growth by inhibiting NPM-ALK phosphorylation without showing overt signs of toxicity or significant compound-related body weight loss.
  • 同义词
    KRCA 0008 | KRCA0008
  • 通路
    Angiogenesis
  • 靶点
    ALK
  • 受体
    ACK|ALK
  • 研究领域
    Cancer
  • 适应症
    ——

化学信息

  • CAS Number
    1472795-20-2
  • 分子量
    609.119
  • 分子式
    C30H37ClN8O4
  • 纯度
    >98% (HPLC)
  • 溶解度
    10 mM in DMSO
  • SMILES
    ClC1=CN=C(NC2=CC=C(N3CCN(C(C)=O)CC3)C=C2OC)N=C1NC4=CC=C(N5CCN(C(C)=O)CC5)C=C4OC
  • 化学全称
    Ethanone, 1,1'-[(5-chloro-2,4-pyrimidinediyl)bis[imino(3-methoxy-4,1-phenylene)-4,1-piperazinediyl]]bis-

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

1. Park CH, et al. Bioorg Med Chem Lett. 2013 Nov 15;23(22):6192-6. 2. Kang CH, et al. Biochem Biophys Res Commun. 2015 Aug 28;464(3):762-7. 3. Lee HJ, et al. Arch Pharm Res. 2014;37(9):1130-8.
产品手册
关联产品
  • GSK1838705A

    GSK1838705A 是一种有效的 IGF-IR 和胰岛素受体 (IR) 特异性抑制剂,IC50 分别为 2.0 和 1.6 nM。

  • INCB-000928

    Zilurgisertib (INCB-000928; NBU-928) 是一种选择性的 ALK 2 抑制剂,用于研究癌症等疾病。

  • Iruplinalkib

    Iruplinalkib (WX-0593) 是一种有效的、选择性的、具有口服活性的 ALK 和 ROS1 酪氨酸激酶抑制剂。Iruplinalkib (WX-0593) 在伴有 ALK 或 ROS1 重排的晚期 NSCLC 中显示出良好的安全性和有希望的抗肿瘤活性。